登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Coagulation Factor III】

Coagulation Factor III信息

英文名称:Tissue factor
中文名称:组织因子
靶点别称:Coagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
上市药物数量:1
临床药物数量:4
最高研发阶段:批准上市

Coagulation Factor III 分子别名

Coagulation Factor III,Tissue Factor,TF,F3,CD142

Coagulation Factor III 分子背景

Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Coagulation Factor III 前沿进展

Coagulation Factor III上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Tisotumab vedotin TF-011-MMAE 批准上市 Genmab HuMax-TF, TIVDAK United States 宫颈癌 Seagen Inc 2021-09-20 卵巢癌, 实体瘤, 食道癌, 头颈部鳞状细胞癌, 胰腺癌, 膀胱癌, 前列腺癌, 腹膜癌, 结直肠癌, 子宫内膜癌, 输卵管癌, 宫颈癌, 非小细胞肺癌 详情

Coagulation Factor III临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
XB-002 ICON-2; XB-002 临床一期 Iconic Therapeutics 实体瘤, 泌尿生殖道肿瘤 详情
ALT-836 cH-36; ALT-836; TNX-832 Sunol Molecular Corp 详情
MORAb-066 MORAb-066 杨森 详情
hI-con1 ICON-1; hI-con1 耶鲁大学 详情
Recombinant NAPc2 AB-201 临床三期 Dendreon Uk Ltd 新型冠状病毒肺炎 详情
MRG004A MRG004A 临床二期 上海美雅珂生物技术有限责任公司 实体瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定